INVA
Innoviva, Inc.
NASDAQ · Healthcare · Biotechnology · US
$21.19
−0.76%Next report
Analyst consensus
- Next report date
- Nov 4, 2026
- EPS estimate
- $0.50
- Revenue estimate
- $115.4M
Latest reported
- Last report date
- Aug 5, 2026
- EPS actual
- $1.14
- EPS estimate
- $0.44
- Revenue actual
- $119.6M
- Revenue estimate
- $111.0M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 9
- EPS misses (12Q)
- 3
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +192.3%
- Revenue beats (12Q)
- 9
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $38
- PT range
- $34 – $42
- Analysts
- 2
2 Buy0 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 4, 2026